融资方面，兰卫医学当日融资买入783.99万元。当前融资余额8821.55万元，占流通市值的2.08%，融资 余额超过近一年50%分位水平，处于较高位。 融券方面，兰卫医学8月25日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量2500.00股，融券余额2.65万元，低于近一年40%分位水平，处于较低位。 截至6月30日，兰卫医学股东户数2.32万，较上期减少3.94%；人均流通股15527股，较上期增加5.51%。 2025年1月-6月，兰卫医学实现营业收入7.59亿元，同比减少14.50%；归母净利润-578.32万元，同比减 少137.08%。 8月25日，兰卫医学涨0.86%，成交额7544.56万元。两融数据显示，当日兰卫医学获融资买入额783.99 万元，融资偿还670.95万元，融资净买入113.05万元。截至8月25日，兰卫医学融资融券余额合计 8824.20万元。 分红方面，兰卫医学A股上市后累计派现3.20亿元。近三年，累计派现2.00亿元。 资料显示，上海兰卫医学检验所股份有限公司位于上海市长宁区临新路268弄1号楼4-9层，成立日期 2007年 ...

Core Insights - The company, Lanwei Medical, provides third-party medical testing and pathology diagnosis services, as well as well-known domestic and international in vitro diagnostic products and research technical services to various medical institutions and research institutes [1][2] - The chairman and general manager, Zeng Weixiong, emphasized the company's commitment to high-quality development guided by precision diagnosis and treatment, leveraging its self-built precision medicine center and research innovation center [1] Group 1 - The company aims to enhance its operational capabilities and improve the efficiency of core service processes [1] - It plans to upgrade the network layout and standardized management of regional testing centers [1] - The company is focused on empowering grassroots healthcare by promoting high-quality medical resources and services [1] Group 2 - Lanwei Medical is positioned as a comprehensive service provider offering integrated solutions for the medical diagnostics industry, ranking among the industry leaders [2] - The company addresses the differentiated needs of its clients through a variety of specialized technical support [2]

Group 1 - The company provides comprehensive solutions for the medical diagnostics industry, offering third-party medical testing and pathology diagnosis services, as well as well-known in vitro diagnostic products and research technical services [3] - The company has developed a systematic, large-scale, and networked service system, which includes five core centers: medical testing center, pathology diagnosis center, precision testing center, academic exchange center, and public health testing center [3] - The company aims to enhance the standardization of grassroots medical laboratories and the professional construction of precision laboratories, integrating high-end medical resources to achieve mutual recognition of medical testing results and collaborative sharing of pathology diagnosis resources [3] Group 2 - The company has changed its accounting firm to Rongcheng Accounting Firm (Special General Partnership) for the current reporting period [1] - The board of directors approved a profit distribution plan, proposing a cash dividend of 2 yuan (including tax) for every 10 shares, with no bonus shares distributed [2] - There are no preferred shareholders or significant changes in the top 10 shareholders during the reporting period [4]